ConductScience.org, home

Paper7614902

Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop.

Richman DD and 1 other. Drugs, 1995. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop. Papers, record 7614902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7614902

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop.
PubMed
Journal
Drugs
PubMed
Year
1995
PubMed
Publication types
Comparative Study, Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S., Review
PubMed
Citations, by iCite
0
iCite
Relative citation ratio, by iCite
0
iCite
Revised in PubMed
2018-11-13
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Richman DDD D
2Havlir DD

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HIV InfectionsMajor topic
ZidovudineMajor topic
CD4 Lymphocyte Count
Clinical Trials as Topic
Humans
Survival Analysis
Time Factors
Virus Replication

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
AI27670NIAID NIH HHSUnited StatesU01AI027670PubMed and NIHNIH RePORTER
AI29164NIAID NIH HHSUnited StatesR01AI029164PubMed and NIHNIH RePORTER
AI30457NIAID NIH HHSUnited StatesU01AI030457PubMed and NIHNIH RePORTER
R37AI029164NIHNIH RePORTER

Download CSV of grants

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11969115
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
N Engl J Med1990https://conductscience.org/library/papers/1969115PubMed
21970466
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
Ann Intern Med1990https://conductscience.org/library/papers/1970466PubMed
37905722
Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
Ann Intern Med1994https://conductscience.org/library/papers/7905722PubMed
41353607A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.N Engl J Med1992https://conductscience.org/library/papers/1353607PubMed
58100611Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.N Engl J Med1993https://conductscience.org/library/papers/8100611PubMed
62191113Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex.J Acquir Immune Defic Syndr (1988)1990https://conductscience.org/library/papers/2191113PubMed
77816094Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.Nature1995https://conductscience.org/library/papers/7816094PubMed
88096089High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.Science1993https://conductscience.org/library/papers/8096089PubMed
98455722HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.Nature1993https://conductscience.org/library/papers/8455722PubMed
103124680Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).Ann Intern Med1988https://conductscience.org/library/papers/3124680PubMed
1180933632',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial.J Infect Dis1993https://conductscience.org/library/papers/8093363PubMed
122510843Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.BMJ1989https://conductscience.org/library/papers/2510843PubMed
132904016Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex.Lancet1988https://conductscience.org/library/papers/2904016PubMed
148093551The immunopathogenesis of human immunodeficiency virus infection.N Engl J Med1993https://conductscience.org/library/papers/8093551PubMed
152891981Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).Lancet1988https://conductscience.org/library/papers/2891981PubMed
167901434
Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients.
JAMA1993https://conductscience.org/library/papers/7901434PubMed
173044087Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection.Am J Med1988https://conductscience.org/library/papers/3044087PubMed
182467383HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.Science1989https://conductscience.org/library/papers/2467383PubMed
198096373CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.Ann Intern Med1993https://conductscience.org/library/papers/8096373PubMed
203299090The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.N Engl J Med1987https://conductscience.org/library/papers/3299090PubMed

See all 35 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7614902

GET https://conductscience.org/api/papers/v1/7614902/references?page=2